REGN logo

REGN
Regeneron Pharmaceuticals, Inc.

17,595
Mkt Cap
$67.37B
Volume
994,957.00
52W High
$821.11
52W Low
$476.49
PE Ratio
15.66
REGN Fundamentals
Price
$638.88
Prev Close
$642.59
Open
$639.24
50D MA
$731.64
Beta
0.63
Avg. Volume
740,870.91
EPS (Annual)
$41.48
P/B
2.15
Rev/Employee
$930,752.76
$78,186.98
Loading...
Loading...
News
all
press releases
Here's Why Regeneron (REGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026...
News Placeholder
BAYRY's Kerendia Label Expansion Application Gets Priority Review
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
News Placeholder
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
read more...
News Placeholder
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are...
News Placeholder
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
News Placeholder
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
News Placeholder
Company News for May 19, 2026
Companies In The Article Are:REGN,D,NEE,STX and BSX
News Placeholder
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations
REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron...
News Placeholder
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN) Regeneron Pharmaceuticals Investigation Initiated: Levi...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available